Semax Peptide: A Research Overview

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro), a research-use analog of the ACTH(4-10) / ACTH(4-7) fragment, studied in laboratory and animal models.

What Is Semax?

Semax is a seven-amino-acid peptide derived from a fragment of adrenocorticotropic hormone (ACTH(4-7)) with a C-terminal Pro-Gly-Pro motif. It is registered and used as a medication in Russia, but in the United States it is not FDA-approved and is handled as a research compound. In the lab it is typically supplied as a lyophilized powder. Much of the published data is preclinical (cell and rodent models) and a large share originates from Russian research groups.

What the Research Describes

Mechanistic studies — in cells and animals — have investigated several overlapping pathways:

• BDNF and trkB expression in rat hippocampus, where a single dose was reported to raise BDNF protein and exon-III BDNF mRNA plus trkB mRNA and phosphorylation, studied in animal tissue.
• Monoaminergic modulation in rodents, including changes in striatal serotonin-metabolite levels and dopaminergic responses in neurochemical models.
• Neuroprotection in cerebral ischemia–reperfusion models (rat tMCAO), where transcriptome and protein-expression analyses reported modulation of neurotrophin and inflammatory pathways.
• Melanocortin / ACTH-analog activity characterized in preclinical work without a reported corticotropic (adrenal-stimulating) effect.
• Resistance to enzymatic degradation, studied biochemically as a feature of the C-terminal Pro-Gly-Pro motif.

These describe mechanisms observed in laboratory and animal research — not demonstrated effects in humans.

A Note on the Current Evidence

• A large share of the Semax literature is Russian-language and originates from a limited set of groups (notably the Institute of Molecular Genetics, Moscow), which limits independent external replication.
• Semax is registered and used as a medicine in Russia, but it has not been FDA-approved and has not been evaluated in large independent Western clinical trials.
• There is a shortage of large, independent, placebo-controlled human trials, so preclinical mechanistic findings should not be extrapolated to human outcomes.

Forms and Handling in Research

In a research setting Semax is handled as a lyophilized (freeze-dried) powder, commonly reconstituted with bacteriostatic water for laboratory use, stored cold and protected from light, and supplied with purity testing (e.g., HPLC) and lot documentation.

Research-Use and Legal Status

Semax is sold and used as a research compound only. It is not an FDA-approved drug, not a dietary supplement, and not intended for human or animal consumption.